// App-Quantinova.ai

TCT-835 : Validation of PARIS Risk Scores in Patients Treated With Everolimus-Eluting Stents for Left Main Coronary Artery Disease: Analysis From the EXCEL Trial

Researchers

Presenter

  • Sabato Sorrentino

Principal Investigators

  • Bimmer Claessen

  • Roxana Mehran

  • David Kandzari

  • Marie-Claude Morice

  • Martin Leon

  • Bernard Gersh

  • Ori Ben-Yehuda

  • Bjorn Redfors

  • Ovidiu Dressler

  • Stuart Pocock

  • A. Pieter Kappetein

  • Joseph Sabik

  • Patrick Serruys

  • Gregg Stone

Medical Centers

  • Icahn School of Medicine at Mount Sinai, New York, New York, United States

  • Columbia University Medical Center/NewYork-Presbyterian Hospital, New York, New York, United States

  • London School of Hygiene and Tropical Medicine, London, United Kingdom

  • Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Hospital, New York, New York, United States

  • CERC, Massy, France

  • Amsterdam Medical Center, Amsterdam, Netherlands

  • Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, Netherlands

  • Piedmont Heart Institute, Atlanta, Georgia, United States

  • Cardiovascular Research Foundation, New York, New York, United States

  • Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio, United States

  • Imperial College, London, United Kingdom

  • Mayo Clinic, Rochester, Minnesota, United States

Locations

  • United States

  • France

  • United Kingdom

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

Disease

  • Left main disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Everolimus

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved